866-997-4948(US-Canada Toll Free)

Renal Cell Carcinoma Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Mar 2013

Category :

Oncology

No. of Pages : 334 Pages


Global Markets Directs, \'Renal Cell Carcinoma Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Renal Cell Carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Renal Cell Carcinoma. 

Renal Cell Carcinoma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Renal Cell Carcinoma.
  • A review of the Renal Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Renal Cell Carcinoma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Renal Cell Carcinoma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Renal Cell Carcinoma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Renal Cell Carcinoma Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Renal Cell Carcinoma 11
Renal Cell Carcinoma Therapeutics under Development by Companies 13
Renal Cell Carcinoma Therapeutics under Investigation by Universities/Institutes 18
Late Stage Products 21
Comparative Analysis 21
Mid Clinical Stage Products 22
Comparative Analysis 22
Early Clinical Stage Products 23
Comparative Analysis 23
Discovery and Pre-Clinical Stage Products 24
Comparative Analysis 24
Renal Cell Carcinoma Therapeutics Products under Development by Companies 25
Renal Cell Carcinoma Therapeutics Products under Investigation by Universities/Institutes 31
Companies Involved in Renal Cell Carcinoma Therapeutics Development 33
Bristol-Myers Squibb Company 33
Boehringer Ingelheim GmbH 34
F. Hoffmann-La Roche Ltd. 35
Kyowa Hakko Kirin Co., Ltd. 36
Amgen Inc. 37
AstraZeneca PLC 38
Eli Lilly and Company 39
GlaxoSmithKline plc 40
Seattle Genetics, Inc. 41
Genentech, Inc. 42
Antigenics, Inc. 43
Inovio Biomedical Corporation 44
Celltrion, Inc. 45
Novartis AG 46
Astellas Pharma Inc. 47
Eisai Co., Ltd. 48
Ono Pharmaceutical Co., Ltd. 49
Pfizer Inc. 50
Taiho Pharmaceutical Co., Ltd. 51
Bayer AG 52
MannKind Corporation 53
Hemispherx Biopharma, Inc. 54
Celldex Therapeutics, Inc. 55
Active Biotech AB 56
AEterna Zentaris Inc. 57
Lorus Therapeutics Inc 58
Lpath, Inc. 59
Bionomics Limited 60
Northwest Biotherapeutics, Inc. 61
Cleveland BioLabs, Inc. 62
Flamel Technologies S.A. 63
Dendreon Corporation 64
Threshold Pharmaceuticals, Inc. 65
Rexahn Pharmaceuticals, Inc. 66
Wilex AG 67
Biotecnol SA 68
Acceleron Pharma, Inc. 69
immatics biotechnologies GmbH 70
Curacyte AG 71
Argos Therapeutics, Inc. 72
Cytheris SA 73
Angiogene Pharmaceuticals Ltd. 74
MacroGenics, Inc. 75
Jennerex Biotherapeutics, Inc. 76
Endocyte, Inc. 77
Advenchen Laboratories, LLC 78
Vaccinogen, Inc. 79
TVAX Biomedical, LLC 80
Tigris Pharmaceuticals, Inc. 81
AVEO Pharmaceuticals, Inc. 82
KAHR medical Ltd. 83
Anaphore, Inc. 84
SAIC-Frederick, Inc. 85
Medical Enzymes AG 86
BiOrion Technologies B.V. 87
Ampio Pharmaceuticals, Inc. 88
Renal Cell Carcinoma Therapeutics Assessment 89
Assessment by Monotherapy Products 89
Assessment by Combination Products 90
Assessment by Route of Administration 91
Assessment by Molecule Type 93
Drug Profiles 96
perifosine - Drug Profile 96
rilotumumab - Drug Profile 99
regorafenib - Drug Profile 101
enzastaurin hydrochloride - Drug Profile 103
sorafenib tosylate - Drug Profile 107
axitinib - Drug Profile 111
sunitinib malate - Drug Profile 114
RG-7422 - Drug Profile 118
cediranib maleate - Drug Profile 120
linifanib - Drug Profile 123
vitespen - Drug Profile 125
CDX-1127 - Drug Profile 127
foretinib - Drug Profile 128
vorsetzumab mafodotin - Drug Profile 130
naptumomab estafenatox - Drug Profile 131
LOR-1284 - Drug Profile 133
MKC1106-PP - Drug Profile 134
Asonep - Drug Profile 136
aldesleukin - Drug Profile 138
dalantercept - Drug Profile 139
IMA-901 - Drug Profile 141
Drug Targeting Carbonic Anhydrase IX - Drug Profile 142
everolimus - Drug Profile 143
ramucirumab - Drug Profile 146
pexastimogene devacirepvec - Drug Profile 150
CDX-014 - Drug Profile 152
CBL-0137 - Drug Profile 153
CXCR4 Antibody - Drug Profile 154
AGS-003 - Drug Profile 155
nintedanib - Drug Profile 157
CYT-107 - Drug Profile 159
GlutaDON - Drug Profile 161
OncoVAX - Drug Profile 163
tivozanib - Drug Profile 165
tivozanib - Drug Profile 168
GFB-204 - Drug Profile 171
girentuximab - Drug Profile 172
EC-17 - Drug Profile 174
Hemoximer - Drug Profile 176
dovitinib lactate - Drug Profile 178
KAHR-101 - Drug Profile 180
BNC-105 - Drug Profile 181
ZD-6126 - Drug Profile 182
ATN-658 - Drug Profile 184
BNC-105P + [everolimus] - Drug Profile 185
medroxyprogesterone - Drug Profile 186
Torisel + Bevacizumab - Drug Profile 187
Autologous Dendritic Cells Pulsed Tumor Lysate + Dendritic Cells + thymosin alpha 1 + [aldesleukin] - Drug Profile 188
CVX-060 + [sunitinib malate] - Drug Profile 190
tivozanib + [temsirolimus] - Drug Profile 192
interferon alfa + [temsirolimus] - Drug Profile 194
MDX-1411 - Drug Profile 195
DC-CIK - Drug Profile 196
enzastaurin hydrochloride + [sunitinib malate] - Drug Profile 197
ixabepilone + [bevacizumab] - Drug Profile 198
bortezomib + [sorafenib tosylate] - Drug Profile 200
B7-1 + [aldesleukin] - Drug Profile 201
nivolumab - Drug Profile 202
erlotinib hydrochloride + imatinib mesylate + [bevacizumab] - Drug Profile 205
nelfinavir mesylate + [temsirolimus] - Drug Profile 206
TH-302 + [sunitinib malate] - Drug Profile 207
lenvatinib + [everolimus] - Drug Profile 209
hydroxychloroquine - Drug Profile 210
bevacizumab - Drug Profile 211
Autologous Tumor Lysate-Dendritic Cell Vaccine + [aldesleukin] + [bevacizumab]+ [interferon alfa-2b] - Drug Profile 215
Autologous Tumor Cell Vaccine + [aldesleukin] + [interferon alfa-2a] - Drug Profile 216
VHL Peptides + [aldesleukin] + [sargramostim] + [Incomplete Freund\'s Adjuvant] - Drug Profile 217
MGA-271 - Drug Profile 219
GM-CAIX - Drug Profile 220
bevacizumab biosimilar - Drug Profile 221
(tegafur + gimeracil + oteracil potassium) - Drug Profile 222
X-82 - Drug Profile 225
Mesenchymal Stem Cells - Drug Profile 227
B7/IL-2 Transfected Allogeneic Tumor Cell Vaccine - Drug Profile 228
ARGX-109 - Drug Profile 229
AL-8326 - Drug Profile 230
BEZ-235 + [everolimus] - Drug Profile 231
AMG-172 - Drug Profile 233
PF-04856884 + [axitinib] - Drug Profile 234
B7/IL-2 Transfected Allogeneic Tumor Cell Vaccine - Drug Profile 235
temsirolimus + trebananib - Drug Profile 236
dalantercept + sunitinib - Drug Profile 237
TVI-Kidney-1 - Drug Profile 238
LY-2510924 - Drug Profile 239
Mobilan - Drug Profile 240
AL-2846 - Drug Profile 241
vorsetzumab mafodotin + [everolimus] - Drug Profile 242
V-934 - Drug Profile 243
NCE-001 - Drug Profile 245
decitabine + romidepsin - Drug Profile 246
R-200 - Drug Profile 247
AGS-16C3F - Drug Profile 248
Anti-PTHrP Antibody - Drug Profile 249
Drugs For Renal Cell Carcinoma - Drug Profile 250
BOT-191 - Drug Profile 251
Renal Cell Carcinoma Therapeutics Drug Profile Updates 252
Renal Cell Carcinoma Therapeutics Discontinued Products 307
Renal Cell Carcinoma Therapeutics - Dormant Products 309
Renal Cell Carcinoma Product Development Milestones 317
Featured News & Press Releases 317

Appendix 326
Methodology 326
Coverage 326
Secondary Research 326
Primary Research 326
Expert Panel Validation 326
Contact Us 327
Disclaimer 327

List of Table


Number of Products Under Development for Renal Cell Carcinoma, H1 2013 18
Products under Development for Renal Cell Carcinoma Comparative Analysis, H1 2013 19
Number of Products under Development by Companies, H1 2013 21
Number of Products under Development by Companies, H1 2013 (Contd..1) 22
Number of Products under Development by Companies, H1 2013 (Contd..2) 23
Number of Products under Development by Companies, H1 2013 (Contd..3) 24
Number of Products under Investigation by Universities/Institutes, H1 2013 26
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 27
Comparative Analysis by Late Stage Development, H1 2013 28
Comparative Analysis by Mid Clinical Stage Development, H1 2013 29
Comparative Analysis by Early Clinical Stage Development, H1 2013 30
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 31
Products under Development by Companies, H1 2013 32
Products under Development by Companies, H1 2013 (Contd..1) 33
Products under Development by Companies, H1 2013 (Contd..2) 34
Products under Development by Companies, H1 2013 (Contd..3) 35
Products under Development by Companies, H1 2013 (Contd..4) 36
Products under Development by Companies, H1 2013 (Contd..5) 37
Products under Investigation by Universities/Institutes, H1 2013 38
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 39
Bristol-Myers Squibb Company, H1 2013 40
Boehringer Ingelheim GmbH, H1 2013 41
F. Hoffmann-La Roche Ltd., H1 2013 42
Kyowa Hakko Kirin Co., Ltd., H1 2013 43
Amgen Inc., H1 2013 44
AstraZeneca PLC, H1 2013 45
Eli Lilly and Company, H1 2013 46
GlaxoSmithKline plc, H1 2013 47
Seattle Genetics, Inc., H1 2013 48
Genentech, Inc., H1 2013 49
Antigenics, Inc., H1 2013 50
Inovio Biomedical Corporation, H1 2013 51
Celltrion, Inc., H1 2013 52
Novartis AG, H1 2013 53
Astellas Pharma Inc., H1 2013 54
Eisai Co., Ltd., H1 2013 55
Ono Pharmaceutical Co., Ltd., H1 2013 56
Pfizer Inc., H1 2013 57
Taiho Pharmaceutical Co., Ltd., H1 2013 58
Bayer AG, H1 2013 59
MannKind Corporation, H1 2013 60
Hemispherx Biopharma, Inc., H1 2013 61
Celldex Therapeutics, Inc., H1 2013 62
Active Biotech AB, H1 2013 63
AEterna Zentaris Inc., H1 2013 64
Lorus Therapeutics Inc, H1 2013 65
Lpath, Inc., H1 2013 66
Bionomics Limited, H1 2013 67
Northwest Biotherapeutics, Inc., H1 2013 68
Cleveland BioLabs, Inc., H1 2013 69
Flamel Technologies S.A., H1 2013 70
Dendreon Corporation, H1 2013 71
Threshold Pharmaceuticals, Inc., H1 2013 72
Rexahn Pharmaceuticals, Inc., H1 2013 73
Wilex AG, H1 2013 74
Biotecnol SA, H1 2013 75
Acceleron Pharma, Inc., H1 2013 76
immatics biotechnologies GmbH, H1 2013 77
Curacyte AG, H1 2013 78
Argos Therapeutics, Inc., H1 2013 79
Cytheris SA, H1 2013 80
Angiogene Pharmaceuticals Ltd., H1 2013 81
MacroGenics, Inc., H1 2013 82
Jennerex Biotherapeutics, Inc., H1 2013 83
Endocyte, Inc., H1 2013 84
Advenchen Laboratories, LLC, H1 2013 85
Vaccinogen, Inc., H1 2013 86
TVAX Biomedical, LLC, H1 2013 87
Tigris Pharmaceuticals, Inc., H1 2013 88
AVEO Pharmaceuticals, Inc., H1 2013 89
KAHR medical Ltd., H1 2013 90
Anaphore, Inc., H1 2013 91
SAIC-Frederick, Inc., H1 2013 92
Medical Enzymes AG, H1 2013 93
BiOrion Technologies B.V., H1 2013 94
Ampio Pharmaceuticals, Inc., H1 2013 95
Assessment by Monotherapy Products, H1 2013 96
Assessment by Combination Products, H1 2013 97
Assessment by Stage and Route of Administration, H1 2013 99
Assessment by Stage and Molecule Type, H1 2013 102
Renal Cell Carcinoma Therapeutics Drug Profile Updates 259
Renal Cell Carcinoma Therapeutics Discontinued Products 314
Renal Cell Carcinoma Therapeutics Discontinued Products (Contd..1) 315
Renal Cell Carcinoma Therapeutics Dormant Products 316
Renal Cell Carcinoma Therapeutics Dormant Products (Contd..1) 317
Renal Cell Carcinoma Therapeutics Dormant Products (Contd..2) 318
Renal Cell Carcinoma Therapeutics Dormant Products (Contd..3) 319
Renal Cell Carcinoma Therapeutics Dormant Products (Contd..4) 320
Renal Cell Carcinoma Therapeutics Dormant Products (Contd..5) 321
Renal Cell Carcinoma Therapeutics Dormant Products (Contd..6) 322
Renal Cell Carcinoma Therapeutics Dormant Products (Contd..7) 323

List of Chart


Number of Products under Development for Renal Cell Carcinoma, H1 2013 18
Products under Development for Renal Cell Carcinoma Comparative Analysis, H1 2013 19
Products under Development by Companies, H1 2013 20
Products under Investigation by Universities/Institutes, H1 2013 25
Late Stage Products, H1 2013 28
Mid Clinical Stage Products, H1 2013 29
Early Clinical Stage Products, H1 2013 30
Discovery and Pre-Clinical Stage Products, H1 2013 31
Assessment by Monotherapy Products, H1 2013 96
Assessment by Combination Products, H1 2013 97
Assessment by Route of Administration, H1 2013 98
Assessment by Stage and Route of Administration, H1 2013 99
Assessment by Molecule Type, H1 2013 100
Assessment by Stage and Molecule Type, H1 2013 101

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *